SRT-055

N/A

Report date: 2023/02/27 14:53:26
NME

Base Information

Drug NameSRT-055
Drug Alias NameSRT-055
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLeucine-rich repeat serine/threonine-protein kinase 2 inhibitorsApoptosis signal-regulating kinase 1 inhibitors
TargetsLeucine-rich repeat serine/threonine-protein kinase 2Apoptosis signal-regulating kinase 1
Therapy Area/IndicationsAmyotrophic Lateral SclerosisParkinson Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesSeal Rock Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesSeal Rock Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral SclerosisParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A